CholecystolithiasisNCT02558556
FALCON: a Multicenter Randomized Controlled Trial
A study testing Laparoscopic Fluorescence Imaging System (Karl Storz) and Indocyanine Green in people with Cholecystolithiasis and Cholecystitis, run by Maastricht University Medical Center at 1 site in Netherlands.
Trial summary
Rationale: Several clinical feasibility studies have shown the potential benefit of near-infrared fluorescence (NIRF) imaging using indocyanine green (ICG) for enhanced and earlier biliary anatomy visualization during laparoscopic cholecystectomy with the aim to reduce the number of vascular and biliary injuries. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cholecystolithiasis, Cholecystitis
- What is being tested?
- Laparoscopic Fluorescence Imaging System (Karl Storz) and Indocyanine Green
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 308 participants
- Where
- 1 siteNetherlands
- Study dates
- Jan 2016to Jul 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Scheduled for elective laparoscopic cholecystectomy
- Normal liver and renal function
- No hypersensitivity for iodine or ICG
- Able to understand nature of the study procedures
- Willing to participate and with written informed consent
- Physical Status Classification: ASA I / ASA II
Who cannot join
- Age < 18 years
- Liver or renal insufficiency
- Known iodine or ICG hypersensitivity
- Pregnancy or breastfeeding
- Not able to understand nature of the study procedure
- Physical Status Classification: ASA III and above
- iv Heparin injection in the last 24 h; (LMWH not contraindicated)
Trial locations and contacts
1 site in 1 country.
Netherlands1 site, 1 recruiting
- Recruiting
Maastricht University Medical Center
Maastricht, Limburg, 6229
Jacqueline van den Bos, MD, 0031613206302, jacqueline.vanden.bos@mumc.nl
About this study
Official title: Near-infrared Fluorescence Cholangiography Assisted Laparoscopic Cholecystectomy Versus Conventional Laparoscopic Cholecystectomy (FALCON): a Multicenter Randomized Controlled Trial
Rationale: Several clinical feasibility studies have shown the potential benefit of near-infrared fluorescence (NIRF) imaging using indocyanine green (ICG) for enhanced and earlier biliary anatomy visualization during laparoscopic cholecystectomy with the aim to reduce the number of vascular and biliary injuries. Although the incidence of injuries is low (0.7%), the impact on patients in terms of morbidity, quality of life and costs are dramatic. The Critical View of Safety (CVS) technique is regarded as the safety valve in conventional laparoscopic cholecystectomy (CLC). It is hypothesized that standard application of near-infrared fluorescence imaging during laparoscopic cholecystectomy can be useful to obtain establishment of CVS (at least 5 minutes) earlier and with more certainty regarding visualization when compared to conventional laparoscopic imaging alone.
Study design: A multicenter randomized controlled trial with two study arms. Patients scheduled for an elective laparoscopic cholecystectomy will be recruited and randomized at the outpatient clinic (n = 308 total). One group will undergo near-infrared fluorescence cholangiography assisted laparoscopic cholecystectomy (NIRF-LC) and the other group will undergo conventional laparoscopic cholecystectomy (CLC).
Read more
Compared with standard care, patients in the NIRF-LC group have to receive one preoperative intravenous injection of ICG. This is the only additional minimally invasive action for the patient. Initially, patients participating in this study will not benefit from the application of NIRFC during the surgical procedure. The administration of ICG and the modified laparoscope itself are not related with any kind of additional risk for the patient.
Despite the encouraging results from several (pre)clinical feasibility studies, wide clinical acceptance of the routine use of ICG fluorescence laparoscopy is still lacking due to the absence of reliable and validated clinical data. A randomized clinical study is desirable to assess the potential added value of the NIRF imaging technique during laparoscopic cholecystectomy. Strong evidence in favor of routine implementation of this new imaging technique during laparoscopic cholecystectomy, will probably lead to worldwide routine application of the NIRF technique. Therewith long term sustainability of this research project is guaranteed.
Read the detailed description
Laparoscopic cholecystectomy (LC) is one of the most commonly performed laparoscopic procedures in gastrointestinal surgery. Bile duct injury during this procedure is rare but constitutes a serious complication (0.3-0.7%) (Flum 2003, Fletcher 1999, Nuzzo 2005 and Waage 2005). Misidentification of the extra-hepatic bile duct anatomy during laparoscopic cholecystectomy is the main cause of bile duct injury (Way 2006).
The Critical View of Safety (CVS) technique, which was first described by Strasberg in 1995 (Strasberg 2003) and recommended by the Dutch Guidelines and Best Practice for laparoscopic cholecystectomy (Lange 2006), was introduced to reduce the risk of bile duct injury. To establish CVS, two windows need to be created: one window between the cystic artery, cystic duct and gallbladder, another window between the cystic artery, gallbladder and liver. The CVS technique is especially aimed at mobilizing the gallbladder neck from the liver, in order to obtain a circumferential identification of the transition of the cystic duct into the gallbladder.
Intraoperative cholangiography has been advised to reduce the risk of bile duct injury (Flum 2003, Buddinhg 2011). However, this radiological imaging of the biliary tree is only used selectively, as the process takes time, radiation exposure is involved and additional equipment and manpower for the procedure are required. Therefore, worldwide consensus about implementation of intraoperative cholangiography is still lacking (Ford 2012).
Near-infrared fluorescence (NIRF) imaging after intravenous injection of indocyanine green (ICG) is a promising new technique for easier intraoperative recognition of the biliary anatomy. It may help improve the outcome of laparoscopic cholecystectomy (Buddingh 2011, Agarwal 2009). ICG is cleared quickly and exclusively by the liver after intravenous administration. Neither radiological support nor additional intervention, such as opening the biliary tree, is required. The NIRF laparoscopy technique using ICG has been evaluated in various animal models (Figueiredo 2010, Figueiredo 2011, Tagaya 2010, Matsui 2010) and in open, laparoscopic, and single-incision laparoscopic cholecystectomy (Tagaya 2010, Ishazawa 2010, Ishazawa 2011 Aoki 2010). Promising results were presented for successful intraoperative identification of the common bile duct and the cystic duct, compared to conventional laparoscopic imaging. Another clinical study showed that the NIRFC technique provides significantly earlier identification of the extra-hepatic bile ducts during the CVS dissection phase: up to 10 minutes earlier identification of cystic duct and common bile duct could be obtained (Schols 2012). Real-time simultaneous imaging of the hepatic and cystic arteries can also be obtained (Ashitate 2011, Mitsuhashi 2008, Schols 2013).
Despite the encouraging results from these (pre)clinical feasibility studies, wide clinical acceptance of the routine use of ICG fluorescence laparoscopy is still lacking due to the absence of reliable clinical data. Therefore, a multicenter randomized clinical study is desirable to assess the potential added value of the fluorescence imaging technique during laparoscopic cholecystectomy in order to perform a more safe procedure leading to a reduction in the vascular and bile duct injuries. This study will compare NIRF assisted laparoscopic cholecystectomy to conventional laparoscopic cholecystectomy.
The main objective of this study is to evaluate whether earlier establishment of Critical View of Safety can be obtained using the NIRF laparoscopy technique during laparoscopic cholecystectomy. This will shorten the operation time, and thereby reduce the cost of the procedure.
Study design: Multicenter randomized controlled trial. 308 patients will be included for randomization. All patients (age >18 years) scheduled for an elective laparoscopic cholecystectomy and meeting the inclusion criteria will be suitable for inclusion. Patients will be included in at least 3 hospitals in The Netherlands: Maastricht University Medical Center+; Leiden University Medical Center; Catharina Hospital.
Treatment of subjects: All operations will be performed by a surgical resident, assisted by a surgeon or surgical resident with a track record of at least 50 laparoscopic cholecystectomies, or will be performed by a surgeon or surgical resident with that track record him/herself. In the CLC group conventional laparoscopic cholecystectomy will be performed using conventional laparoscopic imaging systems. In the NIRF-LC group, using laparoscopic fluorescence imaging systems near-infrared fluorescence cholangiography technique will be conducted to assist during laparoscopic cholecystectomy. To obtain fluorescence imaging of the biliary tract a contrast agent has to be administered. Directly after induction of anesthesia the fluorescent dye, indocyanine green (ICG), will be administered for intraoperative visualization of the extra-hepatic bile ducts with the NIR fluorescence laparoscope. Since many years ICG has been approved for commercial and clinical diagnostic use by the FDA.
Randomization: After inclusion in the study (i.e., after written informed consent is obtained) patients will be randomized to NIRF-LC or CLC group. Randomization will be performed centrally. Computerized treatment allocation will be conducted on the day of surgery. There will be no blinding of patients or surgeons.Stratification factor will be performed for participating center.The experience level of the surgical team will be recorded, but no stratification will take place for this factor, as due to the large volume of patients an even distribution of skill level over both randomization arms in expected. Experience is defined in performing laparoscopic cholecystectomy as first surgeon.
Study procedures: The laparoscopic cholecystectomy procedure itself will not be performed differently than usual. Next, there will not be any radiation involved for the patient. Neither are any psychological or psychiatric investigations involved. Patients are not asked to undergo additional testing after the surgical procedure, they are also not requested to fulfill any questionnaire.
The following procedures will be conducted during this study:
- Preoperative (NIRF-LC group): Directly after induction of anesthesia 1ml (2,5mg/ml) indocyanine green will be administrated via intravenous injection, by the surgeon or surgical trainee (under supervision of the surgeon and the anesthesiologist).
- Intraoperative (CLC and NIRF-LC group): Intraoperatively the PhD researcher / local researcher (to be appointed in each participating center) systematically whether the localization of the common bile duct, cystic duct and cystic artery can be identified at set time points, by both the conventional camera mode (CLC group) and fluorescence camera mode (NIRF-LC group). Also establishment of CVS is registered. For agreement on the identification of the aforementioned structures the attending surgeon is consulted. A structure is scored as 'identified' if its localization is confirmed with great certainty by the experienced surgeon. In case of the common bile duct this does explicitly not mean that it was surgically exposed, as this is contradictory to the CVS-technique. In accordance with regular care, all laparoscopic surgical procedures will be digitally recorded.
- Postoperative qualitative video analysis (CLC and NIRF-LC group)
Performed by expert panel of 3 surgeons:
- Is CVS actually established? (and: at what time is CVS established?)
- Time until identification of the cystic duct, and time until identification of the transition of the cystic duct in the gallbladder during dissection of CVS;
- Time until identification of the cystic artery, and time until identification of the transition of the cystic artery in the gallbladder during dissection of CVS; Postoperative quantitative fluorescence image analysis (NIRF-LC group): For objective assessment of the degree of fluorescence illumination in the extra-hepatic bile ducts and artery, OsiriX 5.5.1 Imaging Software will be used. The fluorescence images will be analyzed by determining target-to-background ratio (TBR). TBR is defined as the mean fluorescence intensity (FI) of two point regions of interest (ROIs) in the target (i.e. CBD, CD or CA) minus the mean fluorescence intensity of two background (BG) ROIs in the liver hilum, divided by the mean fluorescence intensity of the two background ROIs in the liver hilum; in formula: TBR = (FI of target - FI of BG) / FI of BG.
Postoperative registration of secondary endpoints (CLC and NIRF-LC group). The researcher will document the following remaining secondary endpoints: Intraoperative bile leakage from the gallbladder or cystic duct; Bile duct injury; Postoperative length of hospital stay; Complications due to the intravenously injected contrast agent; Conversion to open cholecystectomy; Postoperative complications (until 90 days after surgery) After 90 days the patient will contacted by telephone to register any complications that occurred after the routine visits.
Cost-effectiveness minimisation of the procedure will be calculated, limited to the per-operative period. The observed reduction in time until CVS, calculated in cost per minute use of the operating suite, will be weighed against the extra cost of the use of the equipment and the fluorescent dye.
Postoperative analysis of time measurements (CLC and NIRF-LC group) Regarding the primary and secondary endpoints, a linear regression analysis will be applied for determination of possible significant differences between the time measurements from "first look at liver hilum" until "establishment of CVS" / "identification of transition CD in gallbladder" / "identification of transition CA in gallbladder"; therewith comparing fluorescence laparoscopic imaging with conventional laparoscopic imaging. In case of missing values (which can occur with the expert panel analysis, when the panel concludes that actually no CVS was obtained or the transition of the mentioned structures in the gallbladder had not been properly identified) a Cox regression analysis will be used.
- Conditions
- Cholecystolithiasis, Cholecystitis
- Being tested
- Laparoscopic Fluorescence Imaging System (Karl Storz), Indocyanine Green
- Keywords
- Laparoscopic cholecystectomy (LC), Indocyanine green (ICG), Near-Infrared Fluorescence Imaging (NIRF), Critical View of Safety (CVS)
- Medical subject headings
- Cholecystolithiasis, Cholecystitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Laparoscopic Fluorescence Imaging System (Karl Storz)Device
The Laparoscopic Fluorescence Imaging System (incl. laparoscope, light source, light cable) will supply the needs for near-infrared fluorescence imaging with ICG. The hypothesis is that this device will help in visualizing the anatomical structures such as the common bile duct, which are hard to visualize in white light due to the surrounding tissues.
Indocyanine GreenOther
Also called ICG
Indocyanine Green will be injected intravenously as a contrast agent for the use of the Laparoscopic Fluorescence Imaging System.
| Study group | Role | What they receive |
|---|---|---|
| NIRF-LC | Experimental | This group of patients will undergo near-infrared fluorescence cholangiography assisted laparoscopic cholecystectomy by use of a Laparoscopic Fluorescence Imaging System (Karl Storz), in combination with one intravenous injection of contrast agent ICG. The ICG is given directly after induction of anesthesia in a dose of 1 ml of 2,5 mg/ml solution.
Intraoperatively every 2-5 minutes (more often if desired by surgeon) camera is switched to ICG mode for fluorescence cholangiography, until CVS is established.
Registration of time until establishment of CVS, visualization of the individual structures as described as secondary endpoints, and total operation time will be done.
The complete procedure will be recorded on video. Receives: Device: Laparoscopic Fluorescence Imaging System (Karl Storz); Other: Indocyanine Green |
| CLC | No intervention | This group will undergo conventional laparoscopic cholecystectomy as in standard practice with no other intervention. Registration of time until establishment of CVS, visualization of the individual structures as described as secondary endpoints, and total operation time will be done. The complete procedure will be recorded on video. Postoperatively, as in the NIRF-LC arm, the videos will be analysed to determine whether CVS is actually established, is the transition of the cystic duct into the gallbladder visualized? Is transition of the cystic artery into the gallbladder visualized? Furthermore, cost-minimalisation will be calculated. |
What is being measured
The primary outcome is the main question the study is designed to answer.
time to identification of CVS
change in time to identification of CVS
Measured: at time of surgery
Secondary outcomes (10)
time until identification of the transition of the cystic duct in the gallbladder during dissection of CVS
change in time to identification
Measured: at time of surgery
visualization of CVS and visualization of the transition of the cystic duct and cystic artery in the gallbladder
Are these structures actually visualized?
Measured: at time of surgery
total surgical time
change in duration of surgery
Measured: at time of surgery
intraoperative bile leakage from the gallbladder or cystic duct
change in number of intraoperative bile leakage from the gallbladder or cystic duct
Measured: at time of surgery
bile duct injury
change in number of bile duct injuries
Measured: up to 90 days
postoperative length of hospital stay
change in length of hospital stay
Measured: participants will be followed for the duration of hospital stay, an expected average of 1-2 days
complications due to the injected contrast agent
appearance of complications in intervention group
Measured: at time of surgery
conversion to open cholecystectomy
change in number of conversions
Measured: at time of surgery
postoperative complications
change in number of postoperative complications
Measured: up to 90 days
cost-minimisation: difference in costs between the treatment in both groups
change in costs per patient
Measured: up to 90 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Sep 2015 (estimated)
- Study startJan 2016
- Primary completionDec 2019 (estimated)
- Study completionJul 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (21)Papers the sponsor has linked to this study.
- Other trials for CholecystolithiasisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 308 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Maastricht University Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Laurents PS Stassen, MD, PhD, Principal investigator, Maastricht UMC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02558556
- Sponsor's protocol ID
- NL47718.068.14
- Status last verified
- Mar 2019
- First submitted
- 21 Sep 2015
- Last updated
- 7 Mar 2019
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Flum DR, Dellinger EP, Cheadle A, Chan L, Koepsell T. Intraoperative cholangiography and risk of common bile duct injury during cholecystectomy. JAMA. 2003 Apr 2;289(13):1639-44. doi: 10.1001/jama.289.13.1639.
PubMed 12672731Fletcher DR, Hobbs MS, Tan P, Valinsky LJ, Hockey RL, Pikora TJ, Knuiman MW, Sheiner HJ, Edis A. Complications of cholecystectomy: risks of the laparoscopic approach and protective effects of operative cholangiography: a population-based study. Ann Surg. 1999 Apr;229(4):449-57. doi: 10.1097/00000658-199904000-00001.
PubMed 10203075Nuzzo G, Giuliante F, Giovannini I, Ardito F, D'Acapito F, Vellone M, Murazio M, Capelli G. Bile duct injury during laparoscopic cholecystectomy: results of an Italian national survey on 56 591 cholecystectomies. Arch Surg. 2005 Oct;140(10):986-92. doi: 10.1001/archsurg.140.10.986.
PubMed 16230550Waage A, Nilsson M. Iatrogenic bile duct injury: a population-based study of 152 776 cholecystectomies in the Swedish Inpatient Registry. Arch Surg. 2006 Dec;141(12):1207-13. doi: 10.1001/archsurg.141.12.1207.
PubMed 17178963Way LW, Stewart L, Gantert W, Liu K, Lee CM, Whang K, Hunter JG. Causes and prevention of laparoscopic bile duct injuries: analysis of 252 cases from a human factors and cognitive psychology perspective. Ann Surg. 2003 Apr;237(4):460-9. doi: 10.1097/01.SLA.0000060680.92690.E9.
PubMed 12677139Strasberg SM, Hertl M, Soper NJ. An analysis of the problem of biliary injury during laparoscopic cholecystectomy. J Am Coll Surg. 1995 Jan;180(1):101-25. No abstract available.
PubMed 8000648Buddingh KT, Nieuwenhuijs VB, van Buuren L, Hulscher JB, de Jong JS, van Dam GM. Intraoperative assessment of biliary anatomy for prevention of bile duct injury: a review of current and future patient safety interventions. Surg Endosc. 2011 Aug;25(8):2449-61. doi: 10.1007/s00464-011-1639-8. Epub 2011 Apr 13.
PubMed 21487883Ford JA, Soop M, Du J, Loveday BP, Rodgers M. Systematic review of intraoperative cholangiography in cholecystectomy. Br J Surg. 2012 Feb;99(2):160-7. doi: 10.1002/bjs.7809. Epub 2011 Dec 19.
PubMed 22183717Agarwal BB. Patient safety in laparoscopic cholecystectomy. Arch Surg. 2009 Oct;144(10):979; author reply 979. doi: 10.1001/archsurg.2009.180. No abstract available.
PubMed 19841374Figueiredo JL, Siegel C, Nahrendorf M, Weissleder R. Intraoperative near-infrared fluorescent cholangiography (NIRFC) in mouse models of bile duct injury. World J Surg. 2010 Feb;34(2):336-43. doi: 10.1007/s00268-009-0332-8.
PubMed 20033407Figueiredo JL, Nahrendorf M, Vinegoni C, Weissleder R. Intraoperative near-infrared fluorescent cholangiography (NIRFC) in mouse models of bile duct injury: reply. World J Surg. 2011 Mar;35(3):694-5. doi: 10.1007/s00268-010-0728-5. No abstract available.
PubMed 20645091Tagaya N, Shimoda M, Kato M, Nakagawa A, Abe A, Iwasaki Y, Oishi H, Shirotani N, Kubota K. Intraoperative exploration of biliary anatomy using fluorescence imaging of indocyanine green in experimental and clinical cholecystectomies. J Hepatobiliary Pancreat Sci. 2010 Sep;17(5):595-600. doi: 10.1007/s00534-009-0195-2. Epub 2009 Oct 6.
PubMed 19806299Matsui A, Tanaka E, Choi HS, Winer JH, Kianzad V, Gioux S, Laurence RG, Frangioni JV. Real-time intra-operative near-infrared fluorescence identification of the extrahepatic bile ducts using clinically available contrast agents. Surgery. 2010 Jul;148(1):87-95. doi: 10.1016/j.surg.2009.12.004. Epub 2010 Feb 1.
PubMed 20117813Ishizawa T, Bandai Y, Ijichi M, Kaneko J, Hasegawa K, Kokudo N. Fluorescent cholangiography illuminating the biliary tree during laparoscopic cholecystectomy. Br J Surg. 2010 Sep;97(9):1369-77. doi: 10.1002/bjs.7125.
PubMed 20623766Ishizawa T, Kaneko J, Inoue Y, Takemura N, Seyama Y, Aoki T, Beck Y, Sugawara Y, Hasegawa K, Harada N, Ijichi M, Kusaka K, Shibasaki M, Bandai Y, Kokudo N. Application of fluorescent cholangiography to single-incision laparoscopic cholecystectomy. Surg Endosc. 2011 Aug;25(8):2631-6. doi: 10.1007/s00464-011-1616-2. Epub 2011 Mar 18.
PubMed 21424202
Study at a glance
From the registry record, last updated by the sponsor on 7 Mar 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Near-infrared Fluorescence Cholangiography Assisted Laparoscopic Cholecystectomy Versus Conventional Laparoscopic Cholecystectomy (FALCON): a Multicenter Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT02558556
- Acronym / sponsor ID
- NL47718.068.14
- Conditions
- Cholecystolithiasis, Cholecystitis
- Keywords
- Laparoscopic cholecystectomy (LC), Indocyanine green (ICG), Near-Infrared Fluorescence Imaging (NIRF), Critical View of Safety (CVS)
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 308 participants (estimated)
- Lead sponsor
- Maastricht University Medical CenterUniversity, hospital or other
- Study start
- Jan 2016
- Primary completion
- Dec 2019 (estimated)
- Study completion
- Jul 2020 (estimated)
- First posted
- 24 Sep 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Rationale: Several clinical feasibility studies have shown the potential benefit of near-infrared fluorescence (NIRF) imaging using indocyanine green (ICG) for enhanced and earlier biliary anatomy visualization during laparoscopic cholecystectomy with the aim to reduce the number of vascular and biliary injuries. Although the incidence of injuries is low (0.7%), the impact on patients in terms of morbidity, quality of life and costs are dramatic. The Critical View of Safety (CVS) technique is regarded as the safety valve in conventional laparoscopic cholecystectomy (CLC). It is hypothesized that standard application of near-infrared fluorescence imaging during laparoscopic cholecystectomy can be useful to obtain establishment of CVS (at least 5 minutes) earlier and with more certainty regarding visualization when compared to conventional laparoscopic imaging alone.
Study design: A multicenter randomized controlled trial with two study arms. Patients scheduled for an elective laparoscopic cholecystectomy will be recruited and randomized at the outpatient clinic (n = 308 total). One group will undergo near-infrared fluorescence cholangiography assisted laparoscopic cholecystectomy (NIRF-LC) and the other group will undergo conventional laparoscopic cholecystectomy (CLC).
Compared with standard care, patients in the NIRF-LC group have to receive one preoperative intravenous injection of ICG. This is the only additional minimally invasive action for the patient. Initially, patients participating in this study will not benefit from the application of NIRFC during the surgical procedure. The administration of ICG and the modified laparoscope itself are not related with any kind of additional risk for the patient.
Despite the encouraging results from several (pre)clinical feasibility studies, wide clinical acceptance of the routine use of ICG fluorescence laparoscopy is still lacking due to the absence of reliable and validated clinical data. A randomized clinical study is desirable to assess the potential added value of the NIRF imaging technique during laparoscopic cholecystectomy. Strong evidence in favor of routine implementation of this new imaging technique during laparoscopic cholecystectomy, will probably lead to worldwide routine application of the NIRF technique. Therewith long term sustainability of this research project is guaranteed.
Detailed description
Laparoscopic cholecystectomy (LC) is one of the most commonly performed laparoscopic procedures in gastrointestinal surgery. Bile duct injury during this procedure is rare but constitutes a serious complication (0.3-0.7%) (Flum 2003, Fletcher 1999, Nuzzo 2005 and Waage 2005). Misidentification of the extra-hepatic bile duct anatomy during laparoscopic cholecystectomy is the main cause of bile duct injury (Way 2006).
The Critical View of Safety (CVS) technique, which was first described by Strasberg in 1995 (Strasberg 2003) and recommended by the Dutch Guidelines and Best Practice for laparoscopic cholecystectomy (Lange 2006), was introduced to reduce the risk of bile duct injury. To establish CVS, two windows need to be created: one window between the cystic artery, cystic duct and gallbladder, another window between the cystic artery, gallbladder and liver. The CVS technique is especially aimed at mobilizing the gallbladder neck from the liver, in order to obtain a circumferential identification of the transition of the cystic duct into the gallbladder.
Intraoperative cholangiography has been advised to reduce the risk of bile duct injury (Flum 2003, Buddinhg 2011). However, this radiological imaging of the biliary tree is only used selectively, as the process takes time, radiation exposure is involved and additional equipment and manpower for the procedure are required. Therefore, worldwide consensus about implementation of intraoperative cholangiography is still lacking (Ford 2012).
Near-infrared fluorescence (NIRF) imaging after intravenous injection of indocyanine green (ICG) is a promising new technique for easier intraoperative recognition of the biliary anatomy. It may help improve the outcome of laparoscopic cholecystectomy (Buddingh 2011, Agarwal 2009). ICG is cleared quickly and exclusively by the liver after intravenous administration. Neither radiological support nor additional intervention, such as opening the biliary tree, is required. The NIRF laparoscopy technique using ICG has been evaluated in various animal models (Figueiredo 2010, Figueiredo 2011, Tagaya 2010, Matsui 2010) and in open, laparoscopic, and single-incision laparoscopic cholecystectomy (Tagaya 2010, Ishazawa 2010, Ishazawa 2011 Aoki 2010). Promising results were presented for successful intraoperative identification of the common bile duct and the cystic duct, compared to conventional laparoscopic imaging. Another clinical study showed that the NIRFC technique provides significantly earlier identification of the extra-hepatic bile ducts during the CVS dissection phase: up to 10 minutes earlier identification of cystic duct and common bile duct could be obtained (Schols 2012). Real-time simultaneous imaging of the hepatic and cystic arteries can also be obtained (Ashitate 2011, Mitsuhashi 2008, Schols 2013).
Despite the encouraging results from these (pre)clinical feasibility studies, wide clinical acceptance of the routine use of ICG fluorescence laparoscopy is still lacking due to the absence of reliable clinical data. Therefore, a multicenter randomized clinical study is desirable to assess the potential added value of the fluorescence imaging technique during laparoscopic cholecystectomy in order to perform a more safe procedure leading to a reduction in the vascular and bile duct injuries. This study will compare NIRF assisted laparoscopic cholecystectomy to conventional laparoscopic cholecystectomy.
The main objective of this study is to evaluate whether earlier establishment of Critical View of Safety can be obtained using the NIRF laparoscopy technique during laparoscopic cholecystectomy. This will shorten the operation time, and thereby reduce the cost of the procedure.
Study design: Multicenter randomized controlled trial. 308 patients will be included for randomization. All patients (age >18 years) scheduled for an elective laparoscopic cholecystectomy and meeting the inclusion criteria will be suitable for inclusion. Patients will be included in at least 3 hospitals in The Netherlands: Maastricht University Medical Center+; Leiden University Medical Center; Catharina Hospital.
Treatment of subjects: All operations will be performed by a surgical resident, assisted by a surgeon or surgical resident with a track record of at least 50 laparoscopic cholecystectomies, or will be performed by a surgeon or surgical resident with that track record him/herself. In the CLC group conventional laparoscopic cholecystectomy will be performed using conventional laparoscopic imaging systems. In the NIRF-LC group, using laparoscopic fluorescence imaging systems near-infrared fluorescence cholangiography technique will be conducted to assist during laparoscopic cholecystectomy. To obtain fluorescence imaging of the biliary tract a contrast agent has to be administered. Directly after induction of anesthesia the fluorescent dye, indocyanine green (ICG), will be administered for intraoperative visualization of the extra-hepatic bile ducts with the NIR fluorescence laparoscope. Since many years ICG has been approved for commercial and clinical diagnostic use by the FDA.
Randomization: After inclusion in the study (i.e., after written informed consent is obtained) patients will be randomized to NIRF-LC or CLC group. Randomization will be performed centrally. Computerized treatment allocation will be conducted on the day of surgery. There will be no blinding of patients or surgeons.Stratification factor will be performed for participating center.The experience level of the surgical team will be recorded, but no stratification will take place for this factor, as due to the large volume of patients an even distribution of skill level over both randomization arms in expected. Experience is defined in performing laparoscopic cholecystectomy as first surgeon.
Study procedures: The laparoscopic cholecystectomy procedure itself will not be performed differently than usual. Next, there will not be any radiation involved for the patient. Neither are any psychological or psychiatric investigations involved. Patients are not asked to undergo additional testing after the surgical procedure, they are also not requested to fulfill any questionnaire.
The following procedures will be conducted during this study:
- Preoperative (NIRF-LC group): Directly after induction of anesthesia 1ml (2,5mg/ml) indocyanine green will be administrated via intravenous injection, by the surgeon or surgical trainee (under supervision of the surgeon and the anesthesiologist).
- Intraoperative (CLC and NIRF-LC group): Intraoperatively the PhD researcher / local researcher (to be appointed in each participating center) systematically whether the localization of the common bile duct, cystic duct and cystic artery can be identified at set time points, by both the conventional camera mode (CLC group) and fluorescence camera mode (NIRF-LC group). Also establishment of CVS is registered. For agreement on the identification of the aforementioned structures the attending surgeon is consulted. A structure is scored as 'identified' if its localization is confirmed with great certainty by the experienced surgeon. In case of the common bile duct this does explicitly not mean that it was surgically exposed, as this is contradictory to the CVS-technique. In accordance with regular care, all laparoscopic surgical procedures will be digitally recorded.
- Postoperative qualitative video analysis (CLC and NIRF-LC group)
Performed by expert panel of 3 surgeons:
- Is CVS actually established? (and: at what time is CVS established?)
- Time until identification of the cystic duct, and time until identification of the transition of the cystic duct in the gallbladder during dissection of CVS;
- Time until identification of the cystic artery, and time until identification of the transition of the cystic artery in the gallbladder during dissection of CVS; Postoperative quantitative fluorescence image analysis (NIRF-LC group): For objective assessment of the degree of fluorescence illumination in the extra-hepatic bile ducts and artery, OsiriX 5.5.1 Imaging Software will be used. The fluorescence images will be analyzed by determining target-to-background ratio (TBR). TBR is defined as the mean fluorescence intensity (FI) of two point regions of interest (ROIs) in the target (i.e. CBD, CD or CA) minus the mean fluorescence intensity of two background (BG) ROIs in the liver hilum, divided by the mean fluorescence intensity of the two background ROIs in the liver hilum; in formula: TBR = (FI of target - FI of BG) / FI of BG.
Postoperative registration of secondary endpoints (CLC and NIRF-LC group). The researcher will document the following remaining secondary endpoints: Intraoperative bile leakage from the gallbladder or cystic duct; Bile duct injury; Postoperative length of hospital stay; Complications due to the intravenously injected contrast agent; Conversion to open cholecystectomy; Postoperative complications (until 90 days after surgery) After 90 days the patient will contacted by telephone to register any complications that occurred after the routine visits.
Cost-effectiveness minimisation of the procedure will be calculated, limited to the per-operative period. The observed reduction in time until CVS, calculated in cost per minute use of the operating suite, will be weighed against the extra cost of the use of the equipment and the fluorescent dye.
Postoperative analysis of time measurements (CLC and NIRF-LC group) Regarding the primary and secondary endpoints, a linear regression analysis will be applied for determination of possible significant differences between the time measurements from "first look at liver hilum" until "establishment of CVS" / "identification of transition CD in gallbladder" / "identification of transition CA in gallbladder"; therewith comparing fluorescence laparoscopic imaging with conventional laparoscopic imaging. In case of missing values (which can occur with the expert panel analysis, when the panel concludes that actually no CVS was obtained or the transition of the mentioned structures in the gallbladder had not been properly identified) a Cox regression analysis will be used.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| NIRF-LC | Experimental | Device: Laparoscopic Fluorescence Imaging System (Karl Storz), Other: Indocyanine GreenThis group of patients will undergo near-infrared fluorescence cholangiography assisted laparoscopic cholecystectomy by use of a Laparoscopic Fluorescence Imaging System (Karl Storz), in combination with one intravenous injection of contrast agent ICG. The ICG is given directly after induction of anesthesia in a dose of 1 ml of 2,5 mg/ml solution. Intraoperatively every 2-5 minutes (more often if desired by surgeon) camera is switched to ICG mode for fluorescence cholangiography, until CVS is established. Registration of time until establishment of CVS, visualization of the individual structures as described as secondary endpoints, and total operation time will be done. The complete procedure will be recorded on video. |
| CLC | No intervention | –This group will undergo conventional laparoscopic cholecystectomy as in standard practice with no other intervention. Registration of time until establishment of CVS, visualization of the individual structures as described as secondary endpoints, and total operation time will be done. The complete procedure will be recorded on video. Postoperatively, as in the NIRF-LC arm, the videos will be analysed to determine whether CVS is actually established, is the transition of the cystic duct into the gallbladder visualized? Is transition of the cystic artery into the gallbladder visualized? Furthermore, cost-minimalisation will be calculated. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Scheduled for elective laparoscopic cholecystectomy
- Normal liver and renal function
- No hypersensitivity for iodine or ICG
- Able to understand nature of the study procedures
- Willing to participate and with written informed consent
Key exclusion criteria (7 listed)
- Age < 18 years
- Liver or renal insufficiency
- Known iodine or ICG hypersensitivity
- Pregnancy or breastfeeding
- Not able to understand nature of the study procedure
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Laparoscopic Fluorescence Imaging System (Karl Storz)The Laparoscopic Fluorescence Imaging System (incl. laparoscope, light source, light cable) will supply the needs for near-infrared fluorescence imaging with ICG. The hypothesis is that this device will help in visualizing the anatomical structures such as the common bile duct, which are hard to visualize in white light due to the surrounding tissues. | Device | NIRF-LC |
| Indocyanine GreenAlso: ICGIndocyanine Green will be injected intravenously as a contrast agent for the use of the Laparoscopic Fluorescence Imaging System. | Other | NIRF-LC |
Primary outcome
time to identification of CVS
Time frame: at time of surgery
change in time to identification of CVS
10 secondary outcomes
time until identification of the transition of the cystic duct in the gallbladder during dissection of CVS
Time frame: at time of surgery
visualization of CVS and visualization of the transition of the cystic duct and cystic artery in the gallbladder
Time frame: at time of surgery
total surgical time
Time frame: at time of surgery
intraoperative bile leakage from the gallbladder or cystic duct
Time frame: at time of surgery
bile duct injury
Time frame: up to 90 days
postoperative length of hospital stay
Time frame: participants will be followed for the duration of hospital stay, an expected average of 1-2 days
complications due to the injected contrast agent
Time frame: at time of surgery
conversion to open cholecystectomy
Time frame: at time of surgery
postoperative complications
Time frame: up to 90 days
cost-minimisation: difference in costs between the treatment in both groups
Time frame: up to 90 days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Mar 2019.
- Background: PubMed 12672731Flum DR, Dellinger EP, Cheadle A, Chan L, Koepsell T. Intraoperative cholangiography and risk of common bile duct injury during cholecystectomy. JAMA. 2003 Apr 2;289(13):1639-44. doi: 10.1001/jama.289.13.1639.
- Background: PubMed 10203075Fletcher DR, Hobbs MS, Tan P, Valinsky LJ, Hockey RL, Pikora TJ, Knuiman MW, Sheiner HJ, Edis A. Complications of cholecystectomy: risks of the laparoscopic approach and protective effects of operative cholangiography: a population-based study. Ann Surg. 1999 Apr;229(4):449-57. doi: 10.1097/00000658-199904000-00001.
- Background: PubMed 16230550Nuzzo G, Giuliante F, Giovannini I, Ardito F, D'Acapito F, Vellone M, Murazio M, Capelli G. Bile duct injury during laparoscopic cholecystectomy: results of an Italian national survey on 56 591 cholecystectomies. Arch Surg. 2005 Oct;140(10):986-92. doi: 10.1001/archsurg.140.10.986.
- Background: PubMed 17178963Waage A, Nilsson M. Iatrogenic bile duct injury: a population-based study of 152 776 cholecystectomies in the Swedish Inpatient Registry. Arch Surg. 2006 Dec;141(12):1207-13. doi: 10.1001/archsurg.141.12.1207.
- Background: PubMed 12677139Way LW, Stewart L, Gantert W, Liu K, Lee CM, Whang K, Hunter JG. Causes and prevention of laparoscopic bile duct injuries: analysis of 252 cases from a human factors and cognitive psychology perspective. Ann Surg. 2003 Apr;237(4):460-9. doi: 10.1097/01.SLA.0000060680.92690.E9.
- Background: PubMed 8000648Strasberg SM, Hertl M, Soper NJ. An analysis of the problem of biliary injury during laparoscopic cholecystectomy. J Am Coll Surg. 1995 Jan;180(1):101-25. No abstract available.
- Background: PubMed 21487883Buddingh KT, Nieuwenhuijs VB, van Buuren L, Hulscher JB, de Jong JS, van Dam GM. Intraoperative assessment of biliary anatomy for prevention of bile duct injury: a review of current and future patient safety interventions. Surg Endosc. 2011 Aug;25(8):2449-61. doi: 10.1007/s00464-011-1639-8. Epub 2011 Apr 13.
- Background: PubMed 22183717Ford JA, Soop M, Du J, Loveday BP, Rodgers M. Systematic review of intraoperative cholangiography in cholecystectomy. Br J Surg. 2012 Feb;99(2):160-7. doi: 10.1002/bjs.7809. Epub 2011 Dec 19.
- Background: PubMed 19841374Agarwal BB. Patient safety in laparoscopic cholecystectomy. Arch Surg. 2009 Oct;144(10):979; author reply 979. doi: 10.1001/archsurg.2009.180. No abstract available.
- Background: PubMed 20033407Figueiredo JL, Siegel C, Nahrendorf M, Weissleder R. Intraoperative near-infrared fluorescent cholangiography (NIRFC) in mouse models of bile duct injury. World J Surg. 2010 Feb;34(2):336-43. doi: 10.1007/s00268-009-0332-8.
- Background: PubMed 20645091Figueiredo JL, Nahrendorf M, Vinegoni C, Weissleder R. Intraoperative near-infrared fluorescent cholangiography (NIRFC) in mouse models of bile duct injury: reply. World J Surg. 2011 Mar;35(3):694-5. doi: 10.1007/s00268-010-0728-5. No abstract available.
- Background: PubMed 19806299Tagaya N, Shimoda M, Kato M, Nakagawa A, Abe A, Iwasaki Y, Oishi H, Shirotani N, Kubota K. Intraoperative exploration of biliary anatomy using fluorescence imaging of indocyanine green in experimental and clinical cholecystectomies. J Hepatobiliary Pancreat Sci. 2010 Sep;17(5):595-600. doi: 10.1007/s00534-009-0195-2. Epub 2009 Oct 6.
Related trials for Cholecystolithiasis
Recruiting
Timing of CHolecystectomy In Severe PAncreatitis
Acute Pancreatitis, Cholelithiasis
RecruitingObservational study
Electrosurgical Patterns and Learning Curve in Elective Laparoscopic Cholecystectomy
Cholelithiasis
RecruitingPhase 4
Time to Loss of Consciousness With Remimazolam Versus Propofol for Anesthetic Induction in Laparoscopic Cholecystectomy
Intravenous Anesthesia, Cholelithiasis
Recruiting
Ultrasound-Guided Rectus Sheath Block Versus Local Infiltration
Cholelithiases, Cholecystitis
Active, not recruitingPhase 4
A Randomized Controlled Trial Comparing the Effects of Different Anesthetic Sedatives on PONV in Laparoscopic Cholecystectomy
Cholelithiasis, Postoperative Nausea and Vomiting
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Laurents PS Stassen, MD, PhD principal investigator
Maastricht UMC
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Laparoscopic Fluorescence Imaging System (Karl Storz) and Indocyanine Green in people with Cholecystolithiasis and Cholecystitis, run by Maastricht University Medical Center at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 7 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Jacqueline van den Bos, MD (0031613206302, jacqueline.vanden.bos@mumc.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
time to identification of CVS (time frame: at time of surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02558556, which also lists 21 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Mar 2019.